avVaa World Health Care Products Reports Positive Results of Latest Ad Campaign
Posted on: Thursday, 14 September 2006, 15:01 CDT
LUMBY, BC Canada, Sept. 14 /PRNewswire-FirstCall/ -- avVaa World Health Care Products Inc. (BULLETIN BOARD: AVVW) , a global biotechnology company offering therapeutic, natural skin and health care products, announced today that it has added a number of new customers as a result of its first series of print advertisements for the Company's NeuroSkin line of skin care products.
To-date, as a result of the new advertising campaign, including a full-color, full-page advertisement in US Weekly magazine, avVaa has realized total sales of $4,968.86, with 142 new customers; many of whom have indicated an interest in other avVaa proprietary product lines. avVaa sales representatives are following up on each order to offer additional product sales and ensure complete customer satisfaction.
avVaa Chairman and CEO Jack Farley said, "We couldn't be more pleased with the results of our recent advertising and promotional campaign for NeuroSkin. Because continued use of our products can ensure continued successful treatment, these newest customer orders can be expected to represent as much as $50,000 in sales over the next twelve months, including monthly refill orders and add-on sales.
"As the ad continues to grow in circulation, we aim to triple these sales figures in the coming months, with a target base of 1,000 new customers by the end of the year," said Farley.
The first NeuroSkin advertisement for the Company's unique, natural psoriasis and eczema relief product appeared in the August 7, 2006 issue of US Weekly magazine and a second ad will appear in the September 25, 2006 publication, available September 15, 2006. US Weekly boasts nearly 5.5 million readers throughout the U.S. and Canada and is a popular source for headline and entertainment news around the world. A copy of the advertisement may be viewed online at: http://www.avvaa.com/
avVaa's print campaign for NeuroSkin spray eczema/psoriasis relief, targets consumers aged 18 - 65, as well as parents of children suffering with these skin ailments.
About NeuroSkin
avVaa's proprietary NeuroSkin spray is an over the counter treatment that offers the promise of steroid-free, natural relief for common skin ailments. NeuroSkin is FDA-compliant; using doctor recommended and tested nanotechnology that penetrates skin to provide almost instant relief to a growing market of consumers who suffer with psoriasis, eczema and other skin ailments.
About avVaa World Health Care Products
avVaa World Health Care Products (AVVW) is a global biotechnology company that specializes in effective, all natural, therapeutic skin care products that improve quality of life and well being for consumers. avVaa's patented European skin care formulas are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including: eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin line of skin care products through mass food and drug
channels in the United States and globally. For more information, visit: http://www.avvaa.com/ or http://www.otcfn.com/avvw.
CONTACT:
Jack Farley CEO / President, at 1-866-772-8822 or visit: http://www.avvaa.com/ or http://www.otcfn.com/avvw
Investor Relations: Merle Goertz (West Coast) of avVaa World Health Care Products, 1-604-688-2349; or Rick McCaffrey of OTC Financial Network, 1-781-444-6100 ext. 625.
Safe Harbor: Statements contained in this press release that are not based upon current or historical fact are forward-looking in nature. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of AVVAA World Health Care Products, Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include but are not limited to the ability to procure, properly price, retain, and successfully complete projects, the availability of technical personnel, changes in technology, and competition.
avVaa World Health Care Products Inc.
CONTACT: Jack Farley, CEO/President of avVaa World Health Care Products,+1-866-772-8822; or Merle Goertz (West Coast), of avVaa World Health CareProducts Investor Relations, +1-604-688-2349; or Rick McCaffrey of OTCFinancial Network, +1-781-444-6100, Ext. 625
Web site: http://www.avvaa.com/
Source: PRNewswire-FirstCall
Related Articles
- Safety Product Company Sees Increased Online Sales Resulting from H1N1 Flu
- 'Choose Skin Health' Initiative Kicks Off Second Year
- NBTY Announces Preliminary Unaudited Net Sales Results for November 2008
- Obagi Medical Products Reports Second Quarter 2008 Financial Results
- Neutrogena(R) Partnership For Skin Health Taps Malin Akerman to Educate About Skin Cancer Detection
- Ann Taylor Announces June 2007 Sales Results
- Conn's, Inc. Reports Sales Results for the Quarter and Year Ended January 31, 2007
- From Sick Care to Health Care: The Principal Financial Group Launches a Nationwide Tour to Educate Brokers
- Conn's, Inc. Reports Sales Results for the Quarter and Six Months Ended July 31, 2006 and Updates Annual Guidance
- LPGA Tour Pro Angela Jerman Teamed Up With Dermik Laboratories During Melanoma Month to Benefit the Women's Dermatologic Society, Help Educate Americans About Sun Exposure & Skin Health
 |
 |
User Comments (0)
RSS Feeds